Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (14267)	7/31/2000 10:10:45 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

1 Q without Neuprex expenses,1 more of many without neuprex sales! neuprex is far behind in everything, so is xoma. mycoprex will go nowhere, unless they give it away for nothing, a plain no money agreement. Who in their right mind will pay anything for mycoprex when the original molecule supposedly ideal antibiotic/antishock is just a non-performing one. This was plausible when neuprex was going fast forward, in fast backward mode means nobody will pay anything for mycoprex, there are negotiators in the other side too. Genimune, same story, what is in it that works? nothing, it is just a bunch of patents, unless the taker gets zero expense. Where is the big indication, isn't it time that the big agreement that called for fast development do something? keep waiting for the bax, they will agree to everything xoma pays for! xoma is a $50M fat cow! Yes, they could sign any of the above 10 minutes before the CC, but any of the above is IRRELEVANT. xoma good synchronicity with the market today, I am amazed of the strenthg of the piper piping! But, since when xoma is so nice that they pre-announced a CC to give new good news!